

Ubaldo Bonuccelli

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/583202/publications.pdf>

Version: 2024-02-01

362
papers

16,699
citations

19657

61
h-index

24258

110
g-index

371
all docs

371
docs citations

371
times ranked

19496
citing authors

#	ARTICLE	IF	CITATIONS
1	Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates A β , tau, immunity and lipid processing. <i>Nature Genetics</i> , 2019, 51, 414-430.	21.4	1,962
2	Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. <i>Nature Genetics</i> , 2017, 49, 1373-1384.	21.4	783
3	Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. <i>Lancet Neurology</i> , The, 2007, 6, 305-313.	10.2	598
4	Prevalence of nonmotor symptoms in Parkinson's disease in an international setting; Study using nonmotor symptoms questionnaire in 545 patients. <i>Movement Disorders</i> , 2007, 22, 1623-1629.	3.9	461
5	Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. <i>Lancet Neurology</i> , The, 2010, 9, 969-977.	10.2	377
6	Summary of the recommendations of the <sc>EFNS</sc>/<sc>MDS</sc>â€‹<sc>ES</sc> review on therapeutic management of <sc>P</sc>arkinson's disease. <i>European Journal of Neurology</i> , 2013, 20, 5-15.	3.3	290
7	Perioperative Atrial Fibrillation and the Long-term Risk of Ischemic Stroke. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 616.	7.4	266
8	Randomized trial of safinamide addâ€‹on to levodopa in Parkinson's disease with motor fluctuations. <i>Movement Disorders</i> , 2014, 29, 229-237.	3.9	239
9	Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Societyâ€‹European Section. Part I: early (uncomplicated) Parkinson's disease. <i>European Journal of Neurology</i> , 2006, 13, 1170-1185.	3.3	228
10	Pain as a Nonmotor Symptom of Parkinson Disease. <i>Archives of Neurology</i> , 2008, 65, 1191-4.	4.5	208
11	Twoâ€‹year, randomized, controlled study of safinamide as addâ€‹on to levodopa in mid to late Parkinson's disease. <i>Movement Disorders</i> , 2014, 29, 1273-1280.	3.9	200
12	Mitochondrial DNA haplogroup K is associated with a lower risk of Parkinson's disease in Italians. <i>European Journal of Human Genetics</i> , 2005, 13, 748-752.	2.8	197
13	Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Societyâ€‹European Section (MDSâ€‹ES). Part II: late (complicated) Parkinson's disease. <i>European Journal of Neurology</i> , 2006, 13, 1186-1202.	3.3	183
14	A short scale for the assessment of motor impairments and disabilities in Parkinson's disease: the SPES/SCOPA. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2004, 75, 388-395.	1.9	178
15	Psychiatric comorbidity in a population of Parkinson's disease patients. <i>European Journal of Neurology</i> , 2004, 11, 315-320.	3.3	173
16	REM sleep behaviour disorder in Parkinson's disease: a questionnaire-based study. <i>Neurological Sciences</i> , 2005, 25, 316-321.	1.9	160
17	Gene-Wide Analysis Detects Two New Susceptibility Genes for Alzheimer's Disease. <i>PLoS ONE</i> , 2014, 9, e94661.	2.5	155
18	Impulsivity and compulsivity in drugâ€‹naïve patients with Parkinson's disease. <i>Movement Disorders</i> , 2011, 26, 464-468.	3.9	139

#	ARTICLE	IF	CITATIONS
19	The diverse phenotype and genotype of pantothenate kinase-associated neurodegeneration. <i>Neurology</i> , 2005, 64, 1810-1812.	1.1	136
20	Intravenous amantadine improves levodopa-induced dyskinesias: An acute double-blind placebo-controlled study. <i>Movement Disorders</i> , 2001, 16, 515-520.	3.9	131
21	Mild cognitive impairment and cognitive-motor relationships in newly diagnosed drug-naive patients with Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012, 83, 601-606.	1.9	130
22	A pilot trial of deferiprone for neurodegeneration with brain iron accumulation. <i>Haematologica</i> , 2011, 96, 1708-1711.	3.5	122
23	Early DEtection of wEaring off in Parkinson disease: The DEEP study. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 204-211.	2.2	121
24	ICARUS study: prevalence and clinical features of impulse control disorders in Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 317-324.	1.9	119
25	Neuropathy and levodopa in Parkinson's disease: Evidence from a multicenter study. <i>Movement Disorders</i> , 2013, 28, 1391-1397.	3.9	114
26	MR Imaging of the Substantia Nigra at 7 T Enables Diagnosis of Parkinson Disease. <i>Radiology</i> , 2014, 271, 831-838.	7.3	114
27	Double-blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson's disease. <i>Movement Disorders</i> , 2009, 24, 541-550.	3.9	112
28	Consensus statement on the role of acute dopaminergic challenge in Parkinson's disease. <i>Movement Disorders</i> , 2001, 16, 197-201.	3.9	111
29	Dopaminergic Modulation of Visual-Spatial Working Memory in Parkinson's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2003, 15, 55-66.	1.5	105
30	White Matter Hyperintensities in Parkinson's Disease. <i>Archives of Neurology</i> , 1995, 52, 191.	4.5	104
31	Alzheimer and his disease: a brief history. <i>Neurological Sciences</i> , 2011, 32, 275-279.	1.9	104
32	Tau forms in CSF as a reliable biomarker for progressive supranuclear palsy. <i>Neurology</i> , 2008, 71, 1796-1803.	1.1	101
33	Impulse control disorders in Parkinson's disease: definition, epidemiology, risk factors, neurobiology and management. <i>Parkinsonism and Related Disorders</i> , 2009, 15, S111-S115.	2.2	101
34	SSRIs Do Not Worsen Parkinson's Disease: Evidence from an Open-Label, Prospective Study. <i>Clinical Neuropharmacology</i> , 2001, 24, 221-227.	0.7	97
35	Orthostatic Hypotension in De Novo Parkinson Disease. <i>Archives of Neurology</i> , 2003, 60, 1400.	4.5	93
36	Proton magnetic resonance spectroscopy (¹ H-MRS) of motor cortex and basal ganglia in de novo Parkinson's disease patients. <i>Neurological Sciences</i> , 2001, 22, 69-70.	1.9	86

#	ARTICLE	IF	CITATIONS
37	Mild cognitive impairment and cognitive reserve in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2011, 17, 579-586.	2.2	86
38	COMT inhibition with tolcapone in the treatment algorithm of patients with Parkinson's disease (PD): relevance for motor and non-motor features. <i>Neuropsychiatric Disease and Treatment</i> , 2008, 4, 1.	2.2	85
39	Spontaneous and induced aneuploidy in peripheral blood lymphocytes of patients with Alzheimer's disease. <i>Human Genetics</i> , 1997, 101, 299-305.	3.8	84
40	Dopamine Transporter SPECT Imaging in Corticobasal Syndrome. <i>PLoS ONE</i> , 2011, 6, e18301.	2.5	84
41	Assessment of midbrain atrophy in patients with progressive supranuclear palsy with routine magnetic resonance imaging. <i>Acta Neurologica Scandinavica</i> , 2007, 116, 37-42.	2.1	82
42	New pharmacologic horizons in the treatment of Parkinson disease. <i>Neurology</i> , 2006, 67, S30-8.	1.1	81
43	Pergolide compared with bromocriptine in Parkinson's disease: A multicenter, crossover, controlled study. <i>Movement Disorders</i> , 1994, 9, 431-436.	3.9	80
44	Comparison of 3T and 7T Susceptibility-Weighted Angiography of the Substantia Nigra in Diagnosing Parkinson Disease. <i>American Journal of Neuroradiology</i> , 2015, 36, 461-466.	2.4	80
45	Acute and chronic cognitive effects of levodopa and dopamine agonists on patients with Parkinson's disease: a review. <i>Therapeutic Advances in Psychopharmacology</i> , 2013, 3, 101-113.	2.7	79
46	A Single-Center, Cross-Sectional Prevalence Study of Impulse Control Disorders in Parkinson Disease. <i>Journal of Clinical Psychopharmacology</i> , 2013, 33, 691-694.	1.4	79
47	Diagnostic function of the neuroinflammatory biomarker YKL-40 in Alzheimer's disease and other neurodegenerative diseases. <i>Expert Review of Proteomics</i> , 2017, 14, 285-299.	3.0	78
48	How many parkinsonian patients are suitable candidates for deep brain stimulation of subthalamic nucleus? Results of a questionnaire. <i>Parkinsonism and Related Disorders</i> , 2007, 13, 528-531.	2.2	77
49	White Matter MRI Hyperintensities in a Hundred and Twenty-Nine Consecutive Migraine Patients. <i>Cephalalgia</i> , 1994, 14, 342-345.	3.9	75
50	Differences in nigrostriatal impairment in clinical variants of early Parkinson's disease: evidence from a PET SPECT study. <i>European Journal of Neurology</i> , 2010, 17, 626-630.	3.3	75
51	Progression of brain atrophy in the early stages of Parkinson's disease: A longitudinal tensor-based morphometry study in de novo patients without cognitive impairment. <i>Human Brain Mapping</i> , 2014, 35, 3932-3944.	3.6	75
52	A randomized clinical trial to evaluate the effects of rasagiline on depressive symptoms in non-demented Parkinson's disease patients. <i>European Journal of Neurology</i> , 2015, 22, 1184-1191.	3.3	75
53	PINK1 heterozygous rare variants: prevalence, significance and phenotypic spectrum. <i>Human Mutation</i> , 2008, 29, 565-565.	2.5	74
54	Personality traits in patients with Parkinson's disease: assessment and clinical implications. <i>Journal of Neurology</i> , 2012, 259, 1029-1038.	3.6	74

#	ARTICLE	IF	CITATIONS
55	Theory of Mind in Parkinson's disease. Behavioural Brain Research, 2011, 219, 342-350.	2.2	72
56	Cytogenetic alterations in lymphocytes of Alzheimer's disease and Parkinson's disease patients. Neurological Sciences, 2002, 23, s97-s98.	1.9	71
57	Changes in Pattern Electroretinograms to Equiluminant Red-Green and Blue-Yellow Gratings in Patients with Early Parkinson's Disease. Journal of Clinical Neurophysiology, 2003, 20, 375-381.	1.7	70
58	Prevalence and impact of COVID-19 in Parkinson's disease: evidence from a multi-center survey in Tuscany region. Journal of Neurology, 2021, 268, 1179-1187.	3.6	70
59	Acute and chronic effects of clozapine in essential tremor. Movement Disorders, 1999, 14, 468-472.	3.9	69
60	A Whole-Brain Analysis in De Novo Parkinson Disease. American Journal of Neuroradiology, 2008, 29, 674-680.	2.4	67
61	Association between amantadine and the onset of dementia in Parkinson's disease. Movement Disorders, 2006, 21, 1375-1379.	3.9	66
62	Case-control study of multiple system atrophy. Movement Disorders, 2005, 20, 158-163.	3.9	65
63	Non-rapid eye movement sleep instability in mild cognitive impairment: a pilot study. Sleep Medicine, 2015, 16, 1139-1145.	1.6	65
64	Diurnal Motor Variations to Repeated Doses of Levodopa in Parkinson's Disease. Clinical Neuropharmacology, 2000, 23, 28-33.	0.7	63
65	Methylation analysis of multiple genes in blood DNA of Alzheimer's disease and healthy individuals. Neuroscience Letters, 2015, 600, 143-147.	2.1	63
66	Role of dopamine receptor agonists in the treatment of early Parkinson's disease. Parkinsonism and Related Disorders, 2009, 15, S44-S53.	2.2	62
67	Spinocerebellar ataxia type 2 in southern Italy: a clinical and molecular study of 30 families. Journal of Neurology, 1999, 246, 467-471.	3.6	59
68	The relationship between cerebral vascular disease and parkinsonism: The VADO study. Parkinsonism and Related Disorders, 2012, 18, 775-780.	2.2	58
69	Hearing loss and cognitive decline in older adults: questions and answers. Aging Clinical and Experimental Research, 2014, 26, 567-573.	2.9	58
70	Parkinson's Disease and pathological gambling: Results from a functional MRI study. Movement Disorders, 2010, 25, 2449-2453.	3.9	57
71	Decision making in de novo Parkinson's disease. Movement Disorders, 2010, 25, 1432-1436.	3.9	56
72	Headache, Panic Disorder and Depression: Comorbidity or a Spectrum?. Neuropsychobiology, 1995, 31, 125-129.	1.9	55

#	ARTICLE	IF	CITATIONS
73	Anemia and iron overload due to compound heterozygosity for novel ceruloplasmin mutations. <i>Blood</i> , 2002, 100, 2246-2248.	1.4	54
74	Clinical Pharmacokinetics of Cabergoline. <i>Clinical Pharmacokinetics</i> , 2003, 42, 633-645.	3.5	53
75	Hyperhomocysteinemia in levodopa-treated patients with Parkinson's disease dementia. <i>Movement Disorders</i> , 2009, 24, 1028-1033.	3.9	53
76	Epidemiology of multiple system atrophy. <i>Neurological Sciences</i> , 2001, 22, 97-99.	1.9	52
77	Affective symptoms and cognitive functions in Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2012, 317, 97-102.	0.6	52
78	Mild affective symptoms in de novo Parkinson's disease patients: relationship with dopaminergic dysfunction. <i>European Journal of Neurology</i> , 2013, 20, 480-485.	3.3	52
79	Evaluation of the Short Parkinson's Evaluation Scale. <i>Clinical Neuropharmacology</i> , 1997, 20, 322-337.	0.7	51
80	Chromosome and oxidative damage biomarkers in lymphocytes of Parkinson's disease patients. <i>International Journal of Hygiene and Environmental Health</i> , 2001, 204, 61-66.	4.3	51
81	Cognitive impairment and cardiovascular disease: So near, so far. <i>International Journal of Cardiology</i> , 2014, 175, 21-29.	1.7	51
82	Relationship between neuropsychological impairment and grey and white matter changes in adult-onset myotonic dystrophy type 1. <i>NeuroImage: Clinical</i> , 2016, 12, 190-197.	2.7	51
83	Î±-Synuclein Heterocomplexes with Î²-Amyloid Are Increased in Red Blood Cells of Parkinson's Disease Patients and Correlate with Disease Severity. <i>Frontiers in Molecular Neuroscience</i> , 2018, 11, 53.	2.9	51
84	Dextromethorphan and parkinsonism. <i>Lancet, The</i> , 1992, 340, 53.	13.7	49
85	Paraneoplastic choreic syndrome during non-Hodgkin's lymphoma. <i>Movement Disorders</i> , 2000, 15, 350-352.	3.9	49
86	Quantitative susceptibility mapping in atypical Parkinsonisms. <i>NeuroImage: Clinical</i> , 2019, 24, 101999.	2.7	49
87	Dopamine agonists and delusional jealousy in Parkinson's disease: A cross-sectional prevalence study. <i>Movement Disorders</i> , 2012, 27, 1679-1682.	3.9	48
88	Species differences in the role of excitatory amino acids in experimental parkinsonism. <i>Neuroscience and Biobehavioral Reviews</i> , 1997, 21, 401-415.	6.1	47
89	Abnormal response to photic stimulation in Juvenile Myoclonic Epilepsy: An EEG-MRI study. <i>Epilepsia</i> , 2014, 55, 1038-1047.	5.1	47
90	Levodopa response in dementia with lewy bodies: A 1-year follow-up study. <i>Parkinsonism and Related Disorders</i> , 2010, 16, 522-526.	2.2	45

#	ARTICLE	IF	CITATIONS
91	Essential tremor is a neurodegenerative disease. <i>Journal of Neural Transmission</i> , 2012, 119, 1383-1387.	2.8	44
92	The Neuroanatomy of the Reticular Nucleus Locus Coeruleus in Alzheimer's Disease. <i>Frontiers in Neuroanatomy</i> , 2017, 11, 80.	1.7	44
93	Cytogenetic analysis oxidative damage in lymphocytes of Parkinson's disease patients. <i>Neurological Sciences</i> , 2001, 22, 83-84.	1.9	42
94	Impulse control disorders in Parkinson's disease: the role of personality and cognitive status. <i>Journal of Neurology</i> , 2012, 259, 2269-2277.	3.6	42
95	The path to biomarker-based diagnostic criteria for the spectrum of neurodegenerative diseases. <i>Expert Review of Molecular Diagnostics</i> , 2020, 20, 421-441.	3.1	42
96	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity in mice is enhanced by ethanol or acetaldehyde. <i>Life Sciences</i> , 1987, 40, 827-832.	4.3	41
97	Mexiletine in the Treatment of Torticollis and Generalized Dystonia. <i>Clinical Neuropharmacology</i> , 2000, 23, 186-189.	0.7	41
98	Excessive daytime sleepiness and fatigue in neurological disorders. <i>Sleep and Breathing</i> , 2020, 24, 413-424.	1.7	41
99	Descriptive Epidemiologic Study of Epilepsy Syndromes in a District of Northwest Tuscany, Italy. <i>Epilepsia</i> , 1991, 32, 294-298.	5.1	40
100	Chromatic pattern-reversal electroretinograms (ChPERGs) are spared in multiple system atrophy compared with Parkinson's disease. <i>Neurological Sciences</i> , 2006, 26, 395-401.	1.9	40
101	Oxidative stress and APO E polymorphisms in Alzheimer's disease and in mild cognitive impairment. <i>Free Radical Research</i> , 2013, 47, 569-576.	3.3	40
102	Iowa Gambling Task in Parkinson's Disease. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2011, 33, 395-409.	1.3	39
103	Morphometric and functional MRI changes in essential tremor with and without resting tremor. <i>Journal of Neurology</i> , 2015, 262, 719-728.	3.6	39
104	Two-level diagnostic classification using cerebrospinal fluid YKL40 in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2017, 13, 993-1003.	0.8	39
105	Spectrum of addictions in Parkinson's disease: from dopamine dysregulation syndrome to impulse control disorders. <i>Journal of Neurology</i> , 2010, 257, 276-283.	3.6	38
106	Amitriptyline and Dexamethasone Combined Treatment in Drug-Induced Headache. <i>Cephalalgia</i> , 1996, 16, 197-200.	3.9	37
107	Comparing dopamine agonists in Parkinson's disease. <i>Current Opinion in Neurology</i> , 2003, 16, S13-S19.	3.6	37
108	Dopaminergic degeneration and perfusional impairment in Lewy body dementia and Alzheimer's disease. <i>Neurological Sciences</i> , 2003, 24, 162-163.	1.9	36

#	ARTICLE	IF	CITATIONS
109	Dopamine transporter imaging study in parkinsonism occurring in fragile X premutation carriers. <i>Neurology</i> , 2005, 65, 1971-1973.	1.1	36
110	Multiple system atrophy is distinguished from idiopathic Parkinson's disease by the arginine growth hormone stimulation test. <i>Annals of Neurology</i> , 2006, 60, 611-615.	5.3	36
111	Mitochondrial DNA rearrangements in young onset parkinsonism: two case reports. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2001, 71, 685-687.	1.9	35
112	Predictive value of nigrostriatal dysfunction in isolated tremor: A clinical and SPECT study. <i>Movement Disorders</i> , 2008, 23, 2049-2054.	3.9	35
113	Twinkle mutation in an Italian family with external progressive ophthalmoplegia and parkinsonism: A case report and an update on the state of art. <i>Neuroscience Letters</i> , 2013, 556, 1-4.	2.1	34
114	Plasmatic oxidative stress biomarkers in multiple sclerosis: Relation with clinical and demographic characteristics. <i>Clinical Biochemistry</i> , 2015, 48, 19-23.	1.9	34
115	Operationalizing mild cognitive impairment criteria in small vessel disease: the VMCI-Tuscany Study. , 2016, 12, 407-418.		34
116	Evidence of delayed nigrostriatal dysfunction in corticobasal syndrome: A SPECT follow-up study. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 557-559.	2.2	33
117	Different Clinical Contexts of Use of Blood Neurofilament Light Chain Protein in the Spectrum of Neurodegenerative Diseases. <i>Molecular Neurobiology</i> , 2020, 57, 4667-4691.	4.0	33
118	Amantadine in Huntington's disease: open-label video-blinded study. <i>Neurological Sciences</i> , 2002, 23, s83-s84.	1.9	32
119	Influences of dopaminergic treatment on motor cortex in Parkinson disease: A MRI/MRS study. <i>Movement Disorders</i> , 2007, 22, 2170-2175.	3.9	32
120	Low frequency stimulation of the nucleus tegmenti pedunculopontini increases cortical metabolism in Parkinsonian patients. <i>European Journal of Neurology</i> , 2011, 18, 842-849.	3.3	32
121	Orbital and ventromedial prefrontal cortex functioning in Parkinson's disease: Neuropsychological evidence. <i>Brain and Cognition</i> , 2012, 79, 23-33.	1.8	32
122	Î±-Synuclein Aggregates with Î²-Amyloid or Tau in Human Red Blood Cells: Correlation with Antioxidant Capability and Physical Exercise in Human Healthy Subjects. <i>Molecular Neurobiology</i> , 2018, 55, 2653-2675.	4.0	32
123	Treatment of Patients With Tardive Dystonia With Olanzapine. <i>Clinical Neuropharmacology</i> , 2002, 25, 71-74.	0.7	31
124	The Epidemiology and Clinical Manifestations of Dysexecutive Syndrome in Parkinson's Disease. <i>Frontiers in Neurology</i> , 2012, 3, 159.	2.4	31
125	Diabetes is associated with postural and cognitive domains in Parkinson's disease. Results from a single-center study. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 671-672.	2.2	31
126	Visual hallucinations in Parkinson's disease are not influenced by polymorphisms of serotonin 5-HT2A receptor and transporter genes. <i>Neuroscience Letters</i> , 2007, 422, 228-231.	2.1	30

#	ARTICLE	IF	CITATIONS
127	Decreased and increased cortical activation coexist in de novo Parkinson's disease. <i>Experimental Neurology</i> , 2010, 224, 299-306.	4.1	30
128	The association between motor subtypes and alexithymia in de novo Parkinson's disease. <i>Journal of Neurology</i> , 2011, 258, 1042-1045.	3.6	30
129	Affective theory of mind in patients with Parkinson's disease. <i>Psychiatry and Clinical Neurosciences</i> , 2013, 67, 273-276.	1.8	30
130	Caudate dopaminergic denervation and visual hallucinations: Evidence from a 123I-FP-CIT SPECT study. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 761-765.	2.2	30
131	Social cognition in Juvenile Myoclonic Epilepsy. <i>Epilepsy Research</i> , 2016, 128, 61-67.	1.6	30
132	A review of adverse events linked to dopamine agonists in the treatment of Parkinson's disease. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 181-198.	2.4	30
133	Epidemiology of progressive supranuclear palsy. <i>Neurological Sciences</i> , 2001, 22, 101-103.	1.9	29
134	Hypoactivation of the primary sensorimotor cortex in de novo Parkinson's disease. <i>Neuroradiology</i> , 2012, 54, 261-268.	2.2	29
135	Development and Psychometric Properties of a Neuropsychological Battery for Mild Cognitive Impairment with Small Vessel Disease: The VMCI-Tuscany Study. <i>Journal of Alzheimer's Disease</i> , 2014, 43, 1313-1323.	2.6	29
136	The genetics of ataxia: through the labyrinth of the Minotaur, looking for Ariadne's thread. <i>Journal of Neurology</i> , 2014, 261, 528-541.	3.6	29
137	A longitudinal study of polysomnographic variables in patients with mild cognitive impairment converting to Alzheimer's disease. <i>Journal of Sleep Research</i> , 2019, 28, e12821.	3.2	29
138	Pharmacokinetics and Pharmacodynamics of L-DOPA After Acute and 6-Week Tolcapone Administration in Patients with Parkinson's Disease. <i>Clinical Neuropharmacology</i> , 1999, 22, 24-29.	0.7	28
139	Prevalence of headache syndromes in panic disorder. <i>International Clinical Psychopharmacology</i> , 1999, 14, 247-251.	1.7	28
140	Dopamine agonists in the treatment of Parkinson's disease. <i>Expert Review of Neurotherapeutics</i> , 2006, 6, 81-89.	2.8	28
141	Alexithymia Is Associated with Depression in de novo Parkinson's Disease. <i>Psychotherapy and Psychosomatics</i> , 2011, 80, 251-253.	8.8	28
142	Alzheimer's Pathogenesis and Its Link to the Mitochondrion. <i>Oxidative Medicine and Cellular Longevity</i> , 2015, 2015, 1-8.	4.0	28
143	Activity-Based Diary for Parkinson's Disease. <i>Clinical Neuropharmacology</i> , 2002, 25, 43-50.	0.7	27
144	Pergolide in the Treatment of Patients With Early and Advanced Parkinson's Disease. <i>Clinical Neuropharmacology</i> , 2002, 25, 1-10.	0.7	27

#	ARTICLE	IF	CITATIONS
145	Variant of Rett Syndrome and CDKL5 Gene: Clinical and Autonomic Description of 10 Cases. <i>Neuropediatrics</i> , 2012, 43, 037-043.	0.6	27
146	Alteration of affective theory of mind in amnesic mild cognitive impairment. <i>Journal of Neuropsychology</i> , 2013, 7, 121-131.	1.4	27
147	Genetics of ischaemic stroke in young adults. <i>BBA Clinical</i> , 2015, 3, 96-106.	4.1	27
148	Locus Coeruleus Magnetic Resonance Imaging in Neurological Diseases. <i>Current Neurology and Neuroscience Reports</i> , 2021, 21, 2.	4.2	27
149	The tau gene in progressive supranuclear palsy: exclusion of mutations in coding exons and exon 10 splice sites, and identification of a new intronic variant of the disease-associated H1 haplotype in Italian cases. <i>Neuroscience Letters</i> , 1999, 274, 61-65.	2.1	26
150	Effects of peripheral and central catechol-O-methyltransferase inhibition on striatal extracellular levels of dopamine: a microdialysis study in freely moving rats. <i>Parkinsonism and Related Disorders</i> , 2003, 9, 145-150.	2.2	26
151	The relationship between motor symptom lateralization and cognitive performance in newly diagnosed drug-naïve patients with Parkinson's disease. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2013, 35, 124-131.	1.3	26
152	Vascular Factors and Mitochondrial Dysfunction: a Central Role in the Pathogenesis of Alzheimer's Disease. <i>Current Neurovascular Research</i> , 2013, 10, 76-80.	1.1	26
153	Clinical features associated with ictal osmophobia in migraine. <i>Neurological Sciences</i> , 2015, 36, 43-46.	1.9	26
154	Serotonergic antidepressant drugs and L-dopa-induced dyskinesias in Parkinson's disease. <i>Acta Neurologica Scandinavica</i> , 2015, 131, 191-195.	2.1	26
155	Environmental factors and Parkinson's disease: a case-control study in the Tuscany region of Italy. <i>Parkinsonism and Related Disorders</i> , 2004, 10, 481-485.	2.2	25
156	“Parkinson-dementia” diseases: A comparison by double tracer SPECT studies. <i>Parkinsonism and Related Disorders</i> , 2009, 15, 762-766.	2.2	25
157	A non-comparative assessment of tolerability and efficacy of duloxetine in the treatment of depressed patients with Parkinson's disease. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 2269-2280.	1.8	25
158	Triggers in Allodynic and Non-Allodynic Migraineurs. A Clinic Setting Study. <i>Headache</i> , 2013, 53, 152-160.	3.9	25
159	Recommendations of the Sleep Study Group of the Italian Dementia Research Association (SINDem) on clinical assessment and management of sleep disorders in individuals with mild cognitive impairment and dementia: a clinical review. <i>Neurological Sciences</i> , 2014, 35, 1329-1348.	1.9	25
160	A clinical and laboratory study evaluating the profile of cytokine levels in relapsing remitting and secondary progressive multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2015, 278, 53-59.	2.3	25
161	Association of transient orthostatic hypotension with falls and syncope in patients with Parkinson disease. <i>Neurology</i> , 2020, 95, e2854-e2865.	1.1	25
162	Nummular headache dramatically responsive to indomethacin. <i>Cephalalgia</i> , 2010, 30, 1151-1152.	3.9	24

#	ARTICLE	IF	CITATIONS
163	Diagnosis of possible Mild Cognitive Impairment in Parkinson's disease: Validity of the SCOPA-Cog. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 1160-1163.	2.2	24
164	Levodopa and neuropathy risk in patients with Parkinson disease: Effect of COMT inhibition. <i>Parkinsonism and Related Disorders</i> , 2016, 27, 81-84.	2.2	24
165	Potential Diagnostic Value of Red Blood Cells α -Synuclein Heteroaggregates in Alzheimer's Disease. <i>Molecular Neurobiology</i> , 2019, 56, 6451-6459.	4.0	24
166	How Aware Are Migraineurs of Their Triggers?. <i>Headache</i> , 2013, 53, 834-837.	3.9	23
167	Behavioral and Psychological Symptoms of Dementia: Factor Analysis and Relationship with Cognitive Impairment. <i>European Neurology</i> , 2013, 69, 76-82.	1.4	23
168	Reliability of administrative data for the identification of Parkinson's disease cohorts. <i>Neurological Sciences</i> , 2015, 36, 783-786.	1.9	23
169	Mesolimbic dopaminergic dysfunction in Parkinson's disease depression: evidence from a 123I-FP-CIT SPECT investigation. <i>Journal of Neural Transmission</i> , 2015, 122, 1143-1147.	2.8	23
170	Seven tesla MRI of the substantia nigra in patients with rapid eye movement sleep behavior disorder. <i>Parkinsonism and Related Disorders</i> , 2017, 43, 105-109.	2.2	23
171	Insomnia and hot flashes. <i>Maturitas</i> , 2019, 126, 51-54.	2.4	23
172	Possible Involvement of Dopaminergic Mechanisms in the Antimigraine Action of Flunarizine. <i>Cephalalgia</i> , 1990, 10, 3-8.	3.9	22
173	Platelet monoamine oxidase B activity in parkinsonian patients.. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1990, 53, 854-855.	1.9	22
174	Long-term Follow-up after Flunarizine or Nimodipine Discontinuation in Migraine Patients. <i>Cephalalgia</i> , 1996, 16, 337-340.	3.9	22
175	Prefrontal cortex, dopamine, and jealousy endophenotype. <i>CNS Spectrums</i> , 2013, 18, 6-14.	1.2	22
176	Hereditary spastic paraparesis in adults. A clinical and genetic perspective from Tuscany. <i>Clinical Neurology and Neurosurgery</i> , 2014, 120, 14-19.	1.4	22
177	Biomarker-guided classification scheme of neurodegenerative diseases. <i>Journal of Sport and Health Science</i> , 2016, 5, 383-387.	6.5	22
178	Mapping Cortical Degeneration in ALS with Magnetization Transfer Ratio and Voxel-Based Morphometry. <i>PLoS ONE</i> , 2013, 8, e68279.	2.5	22
179	Domperidone-induced acute dystonia and polycystic ovary syndrome. <i>Movement Disorders</i> , 1991, 6, 79-81.	3.9	21
180	Apomorphine hydrochloride for the treatment of Parkinson's disease. <i>Expert Review of Neurotherapeutics</i> , 2015, 15, 723-732.	2.8	21

#	ARTICLE	IF	CITATIONS
181	Thyroid hormone levels in the cerebrospinal fluid correlate with disease severity in euthyroid patients with Alzheimer's disease. <i>Endocrine</i> , 2017, 55, 981-984.	2.3	21
182	Therapeutic efficacy of a partial dopamine agonist in drug-free parkinsonian patients. <i>Journal of Neural Transmission</i> , 1985, 64, 105-111.	2.8	20
183	Brain perfusion effects of cholinesterase inhibitors in Parkinson's disease with dementia. <i>Journal of Neural Transmission</i> , 2006, 113, 1787-1790.	2.8	20
184	Olfactory evaluation in Mild Cognitive Impairment: correlation with neurocognitive performance and endothelial function. <i>European Journal of Neuroscience</i> , 2017, 45, 1279-1288.	2.6	20
185	Treatment of epilepsy in patients with Alzheimer's disease. <i>Expert Review of Neurotherapeutics</i> , 2017, 17, 309-318.	2.8	20
186	Multicenter Study on Sleep and Circadian Alterations as Objective Markers of Mild Cognitive Impairment and Alzheimer's Disease Reveals Sex Differences. <i>Journal of Alzheimer's Disease</i> , 2020, 78, 1707-1719.	2.6	20
187	Clinical diagnosis of multiple system atrophy: level of agreement between Quinn's criteria and the consensus conference guidelines. <i>Acta Neurologica Scandinavica</i> , 2001, 103, 261-264.	2.1	18
188	Indotest in Atypical Hemispheric Continuity. <i>Cephalalgia</i> , 2008, 28, 300-301.	3.9	18
189	A Combination of CSF Tau Ratio and Midsagittal Midbrain Atrophy for the Early Diagnosis of Progressive Supranuclear Palsy. <i>Journal of Alzheimer's Disease</i> , 2010, 22, 195-203.	2.6	18
190	Observational study of sleep-related disorders in Italian patients with Parkinson's disease: usefulness of the Italian version of Parkinson's disease sleep scale. <i>Neurological Sciences</i> , 2012, 33, 689-694.	1.9	18
191	Nigral anatomy and striatal denervation in genetic Parkinsonism: A family report. <i>Movement Disorders</i> , 2015, 30, 1148-1149.	3.9	18
192	Vascular Function Is Improved After an Environmental Enrichment Program. <i>Hypertension</i> , 2018, 71, 1218-1225.	2.7	18
193	Î±-Synuclein Aggregated with Tau and Î²-Amyloid in Human Platelets from Healthy Subjects: Correlation with Physical Exercise. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 17.	3.4	18
194	Plasma Levels of Oxidative Stress Markers, before and after BoNT/A Treatment, in Chronic Migraine. <i>Toxins</i> , 2019, 11, 608.	3.4	18
195	Platelet peripheral benzodiazepine receptors are decreased in Parkinson's disease. <i>Life Sciences</i> , 1991, 48, 1185-1190.	4.3	17
196	Flunarizine in Migraine Prophylaxis: Predictive Factors for A Positive Response. <i>Cephalalgia</i> , 1998, 18, 349-352.	3.9	17
197	The hOGG1 Ser326Cys polymorphism is not associated with sporadic Parkinson's disease. <i>Neuroscience Letters</i> , 2010, 473, 248-251.	2.1	17
198	Postpartum Headache Due to Spontaneous Cervical Artery Dissection. <i>Headache</i> , 2011, 51, 809-813.	3.9	17

#	ARTICLE	IF	CITATIONS
199	Dopamine Transporter, Age, and Motor Complications in Parkinson's Disease: A Clinical and Single-Photon Emission Computed Tomography Study. <i>Movement Disorders</i> , 2020, 35, 1028-1036.	3.9	17
200	Early autonomic and cognitive dysfunction in PD, DLB and MSA: blurring the boundaries between α -synucleinopathies. <i>Journal of Neurology</i> , 2020, 267, 3444-3456.	3.6	17
201	Apomorphine in malignant syndrome due to levodopa withdrawal. <i>Italian Journal of Neurological Sciences</i> , 1992, 13, 169-170.	0.1	16
202	Phenobarbital in the prophylaxis of late posttraumatic seizures. <i>Italian Journal of Neurological Sciences</i> , 1992, 13, 755-760.	0.1	16
203	No evidence of association between CAG expansions and essential tremor in a large cohort of Italian patients. <i>Journal of Neural Transmission</i> , 2001, 108, 297-304.	2.8	16
204	Validation and attempts of revision of the MDS-recommended tests for the screening of Parkinson's disease dementia. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 32-36.	2.2	16
205	Nigral involvement in atypical parkinsonisms: evidence from a pilot study with ultra-high field MRI. <i>Journal of Neural Transmission</i> , 2016, 123, 509-513.	2.8	16
206	Methylation analysis of DNA repair genes in Alzheimer's disease. <i>Mechanisms of Ageing and Development</i> , 2017, 161, 105-111.	4.6	16
207	A single center study: A β 42/p-Tau181 CSF ratio to discriminate AD from FTD in clinical setting. <i>Neurological Sciences</i> , 2017, 38, 1791-1797.	1.9	16
208	Platelet 3H-Imipramine Binding and Sulphotransferase Activity in Primary Headache. <i>Cephalalgia</i> , 1994, 14, 210-214.	3.9	15
209	Validation of the Guidelines for the Diagnosis of Dementia and Alzheimer's Disease of the Italian Neurological Society. Study in 72 Italian neurological centres and 1549 patients. <i>Neurological Sciences</i> , 2004, 25, 289-295.	1.9	15
210	Neuroleptic Malignant Syndrome: Further Lessons From a Case Report. <i>Psychosomatics</i> , 2010, 51, 349-354.	2.5	15
211	3-T Magnetic Resonance Angiography in Primary Angiitis of the Central Nervous System. <i>Journal of Computer Assisted Tomography</i> , 2013, 37, 493-498.	0.9	15
212	What is the role for EEG after sleep deprivation in the diagnosis of epilepsy? Issues, controversies, and future directions. <i>Neuroscience and Biobehavioral Reviews</i> , 2014, 47, 533-548.	6.1	15
213	Epilepsy occurrence in patients with Alzheimer's disease: clinical experience in a tertiary dementia center. <i>Neurological Sciences</i> , 2016, 37, 645-647.	1.9	15
214	Oxidative Stress Assessment in Alzheimer's Disease: A Clinic Setting Study. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2018, 33, 35-41.	1.9	15
215	Effects of combined training on neuropsychiatric symptoms and quality of life in patients with cognitive decline. <i>Ageing Clinical and Experimental Research</i> , 2021, 33, 1249-1257.	2.9	15
216	Prolactin Secretion in Epileptic Subjects Treated with Phenobarbital: Sex Differences and Circadian Periodicity. <i>Epilepsia</i> , 1986, 27, 142-148.	5.1	14

#	ARTICLE	IF	CITATIONS
217	Naloxone Partly Counteracts Apomorphine Side Effects. <i>Clinical Neuropharmacology</i> , 1991, 14, 442-449.	0.7	14
218	The neuropsychological correlates of pathological lying: evidence from behavioral variant frontotemporal dementia. <i>Journal of Neurology</i> , 2011, 258, 2009-2013.	3.6	14
219	Diagnosis, assessment and management of delusional jealousy in Parkinson's disease with and without dementia. <i>Neurological Sciences</i> , 2013, 34, 1537-1541.	1.9	14
220	fMRI changes in cortical activation during task performance with the unaffected hand partially reverse after ropinirole treatment in de novo Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 265-268.	2.2	14
221	Occurrence of Takotsubo syndrome in a patient with Parkinson's disease after entacapone add-on. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 1313-1314.	2.2	14
222	Disruption of sleep-wake continuum in myotonic dystrophy type 1: Beyond conventional sleep staging. <i>Neuromuscular Disorders</i> , 2018, 28, 414-421.	0.6	14
223	Social cognition in idiopathic generalized epilepsies and potential neuroanatomical correlates. <i>Epilepsy and Behavior</i> , 2019, 100, 106118.	1.7	14
224	Current treatment and future prospects of dopa-induced dyskinesias. <i>Drugs of Today</i> , 2015, 51, 315.	1.1	14
225	Increased platelet 3H-imipramine binding and monoamine oxidase B activity in Alzheimer's disease. <i>Journal of Neural Transmission Parkinson's Disease and Dementia Section</i> , 1990, 2, 139-147.	1.2	13
226	Bedtime cabergoline in Parkinson's disease patients with excessive daytime sleepiness induced by dopamine agonists. <i>Neurological Sciences</i> , 2003, 24, 170-171.	1.9	13
227	Molecular implications of the human glutathione transferase A-4 gene (hGSTA4) polymorphisms in neurodegenerative diseases. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 2005, 579, 107-114.	1.0	13
228	Subcutaneous Apomorphine for Neuroleptic Malignant Syndrome. <i>American Journal of Psychiatry</i> , 2006, 163, 1450-1451.	7.2	13
229	Role of dopamine agonists in Parkinson's disease: an update. <i>Expert Review of Neurotherapeutics</i> , 2007, 7, 1391-1399.	2.8	13
230	A case of sarcoidosis presenting as a non-specific intramedullary lesion. <i>European Journal of Neurology</i> , 2007, 14, 346-349.	3.3	13
231	The mtDNA A8344G α -MERRF-mutation is not a common cause of sporadic Parkinson disease in Italian population. <i>Parkinsonism and Related Disorders</i> , 2008, 14, 381-382.	2.2	13
232	Prevalence of Parkinson's disease and other types of parkinsonism in the Aeolian Archipelago, Sicily. <i>Parkinsonism and Related Disorders</i> , 2008, 14, 572-575.	2.2	13
233	Alexithymia Is Associated With Impulsivity in Newly-Diagnosed, Drug-Naïve Patients With Parkinson's Disease: An Affective Risk Factor for the Development of Impulse-Control Disorders?. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2012, 24, E36-E37.	1.8	13
234	Cognitive correlates of negative symptoms in behavioral variant frontotemporal dementia: implications for the frontal lobe syndrome. <i>Neurological Sciences</i> , 2013, 34, 1893-1896.	1.9	13

#	ARTICLE	IF	CITATIONS
235	Nigral involvement and nigrostriatal dysfunction in Huntington's disease: Evidences from an MRI and SPECT study. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 800-805.	2.2	13
236	Evidences of Reduced Antioxidant Activity in Patients With Chronic Migraine and Medicationâ€™Overuse Headache. <i>Headache</i> , 2015, 55, 984-991.	3.9	13
237	Cyclic alternating pattern and interictal epileptiform discharges during morning sleep after sleep deprivation in temporal lobe epilepsy. <i>Epilepsy and Behavior</i> , 2017, 73, 131-136.	1.7	13
238	Application of the DSM-5 Criteria for Major Neurocognitive Disorder to Vascular MCI Patients. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2018, 8, 104-116.	1.3	13
239	The Precuneus â€™ A Witness for Excessive AÎ² Gathering in Alzheimerâ€™s Disease Pathology. <i>Neurodegenerative Diseases</i> , 2018, 18, 302-309.	1.4	13
240	Clinical Correlates of Cerebral Amyloid Deposition in Parkinsonâ€™s Disease Dementia: Evidence from a PET Study. <i>Journal of Alzheimer's Disease</i> , 2019, 70, 597-609.	2.6	13
241	Preferential occurrence of attacks during night sleep and/or upon awakening negatively affects migraine clinical presentation. <i>Functional Neurology</i> , 2015, 30, 119-23.	1.3	13
242	Transcranial Direct Current Stimulation (tDCS) as a Useful Rehabilitation Strategy to Improve Cognition in Patients With Alzheimer's Disease and Parkinson's Disease: An Updated Systematic Review of Randomized Controlled Trials. <i>Frontiers in Neurology</i> , 2021, 12, 798191.	2.4	13
243	Involvement of monoamine oxidase enzymes in the action of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine, a selective neurotoxin, in the squirrel monkey: Binding and biochemical studies. <i>Brain Research</i> , 1986, 378, 320-324.	2.2	12
244	Dextromethorphan prevents the diethylthiocarbamate enhancement of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity in mice. <i>Brain Research</i> , 2003, 973, 298-302.	2.2	12
245	â€™Airplane headacheâ€™ with aura. <i>Cephalalgia</i> , 2010, 30, 624-625.	3.9	12
246	Event-Based Prospective Memory in Newly Diagnosed, Drug-Naive Parkinson's Disease Patients. <i>Journal of the International Neuropsychological Society</i> , 2011, 17, 1158-1162.	1.8	12
247	Validity and metric of MiniMental Parkinson and MiniMental State Examination in Parkinsonâ€™s disease. <i>Neurological Sciences</i> , 2013, 34, 1751-1758.	1.9	12
248	Concomitant development of hypersexuality and delusional jealousy in patients with Parkinson's disease: A case series. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 1290-1292.	2.2	12
249	P2X7 receptor/NLRP3 inflammasome complex and Î±â€™synuclein in peripheral blood mononuclear cells: a prospective study in neoâ€™diagnosed, treatmentâ€™naïve Parkinsonâ€™s disease. <i>European Journal of Neurology</i> , 2021, 28, 2648-2656.	3.3	12
250	Adrenomyeloneurodystrophy with late cerebral involvement and evidence of a multiple autoimmune disorder. <i>Journal of Inherited Metabolic Disease</i> , 1988, 11, 169-172.	3.6	11
251	Reduced luteinizing hormone secretion in women with Parkinson's disease. <i>Journal of Neural Transmission Parkinson's Disease and Dementia Section</i> , 1990, 2, 225-231.	1.2	11
252	Effect of naloxone on body temperature in postmenopausal women with Parkinson's disease. <i>Life Sciences</i> , 1990, 46, 1241-1247.	4.3	11

#	ARTICLE	IF	CITATIONS
253	Comparison of the Unified Parkinson's Disease Rating Scale and the Short Parkinson's Evaluation Scale in Patients With Parkinson's Disease After Levodopa Loading. <i>Clinical Neuropharmacology</i> , 2002, 25, 83-88.	0.7	11
254	The arginine growth hormone stimulation test in bradykineticâ€rigid parkinsonisms. <i>Movement Disorders</i> , 2008, 23, 190-194.	3.9	11
255	Mitochondrial DNA haplogroups do not influence the Huntington's disease phenotype. <i>Neuroscience Letters</i> , 2008, 444, 83-86.	2.1	11
256	Bilateral thalamic glioma presenting with parkinsonism. <i>Movement Disorders</i> , 2009, 24, 2168-2169.	3.9	11
257	Bilateral Thalamic Infarct Caused by Spontaneous Vertebral Artery Dissection in Pre-eclampsia with HELLP Syndrome: A Previously Unreported Association. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2012, 21, 914.e9-914.e10.	1.6	11
258	Impact of ApoE Polymorphism and Physical Activity on Plasma Antioxidant Capability and Erythrocyte Membranes. <i>Antioxidants</i> , 2019, 8, 538.	5.1	11
259	Apolipoprotein E Polymorphism and Oxidative Stress in Human Peripheral Blood Cells: Can Physical Activity Reactivate the Proteasome System through Epigenetic Mechanisms?. <i>Oxidative Medicine and Cellular Longevity</i> , 2021, 2021, 1-16.	4.0	11
260	Myopathic Involvement and Mitochondrial Pathology in Kennedy Disease and in Other Motor Neuron Diseases. <i>Current Molecular Medicine</i> , 2014, 14, 598-602.	1.3	11
261	Non-pharmacological interventions for Parkinson's disease mild cognitive impairment: future directions for research. <i>Neural Regeneration Research</i> , 2020, 15, 1650.	3.0	11
262	Flunarizine increases PRL secretion in normal and in migraineous women. <i>Journal of Neural Transmission</i> , 1988, 74, 43-53.	2.8	10
263	Oral Thyrotropin-Releasing Hormone Treatment in Inherited Ataxias. <i>Clinical Neuropharmacology</i> , 1988, 11, 520-528.	0.7	10
264	Nonmotor symptoms in Parkinsonâ€™s disease: the dark side of the moon. <i>Future Neurology</i> , 2010, 5, 851-871.	0.5	10
265	Effect of metadoxine on striatal dopamine levels in C57 Black mice. <i>Journal of Pharmacy and Pharmacology</i> , 2011, 45, 476-478.	2.4	10
266	The â€œClosing-Inâ€•Phenomenon in Parkinsonâ€™s Disease Dementia and Lewy-Body Dementia. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2012, 24, E38-E39.	1.8	10
267	Expanding the clinical phenotype of <i>DYT5</i> mutations: Is multiple system atrophy a possible one?. <i>Neurology</i> , 2013, 81, 301-302.	1.1	10
268	Symptomatic orthostatic tremor associated with Gravesâ€™ disease. <i>Neurological Sciences</i> , 2014, 35, 929-931.	1.9	10
269	Present and Future of Ultra-High Field MRI in Neurodegenerative Disorders. <i>Current Neurology and Neuroscience Reports</i> , 2018, 18, 31.	4.2	10
270	A neurotropic approach to the treatment of multi-infarct dementia using L-Î±-glycerylphosphorylcholine. <i>Current Therapeutic Research</i> , 1992, 52, 741-752.	1.2	9

#	ARTICLE	IF	CITATIONS
271	Myopathic involvement in two cases of Hallervorden-Spatz disease. <i>Brain and Development</i> , 1995, 17, 286-290.	1.1	9
272	The safety of dopamine agonists in the treatment of Parkinson's disease. <i>Expert Opinion on Drug Safety</i> , 2008, 7, 111-127.	2.4	9
273	Cerebellar Ataxia with Complete Clinical Recovery and Resolution of MRI Lesions Related to Central Pontine Myelinolysis: Case Report and Literature Review. <i>Case Reports in Neurology</i> , 2010, 2, 157-162.	0.7	9
274	Mild cognitive impairment in De Novo Parkinson's disease according to movement disorder guidelines. <i>Movement Disorders</i> , 2012, 27, 1706-1706.	3.9	9
275	Depressive symptoms in Parkinson's disease. <i>Comprehensive Psychiatry</i> , 2012, 53, 727-731.	3.1	9
276	Localized Calcific Hematoma of the Scalp Presenting as a Nummular-Like Headache. A Case Report. <i>Headache</i> , 2014, 54, 370-372.	3.9	9
277	Cerebral sinus venous thrombosis. <i>Blood Coagulation and Fibrinolysis</i> , 2015, 26, 505-508.	1.0	9
278	Relation between plasmatic and cerebrospinal fluid oxidative stress biomarkers and intrathecal Ig synthesis in Multiple Sclerosis patients. <i>Journal of Neuroimmunology</i> , 2015, 283, 39-42.	2.3	9
279	Detecting cognitive impairment at the early stages: The challenge of first line assessment. <i>Journal of the Neurological Sciences</i> , 2017, 377, 12-18.	0.6	9
280	Advances in the pharmacotherapeutic management of dementia with Lewy bodies. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 1643-1653.	1.8	9
281	Aerobic Exercise and Healthy Nutrition as Neuroprotective Agents for Brain Health in Patients with Parkinson's Disease: A Critical Review of the Literature. <i>Antioxidants</i> , 2020, 9, 380.	5.1	9
282	Î±-Synuclein Heteromers in Red Blood Cells of Alzheimer's Disease and Lewy Body Dementia Patients. <i>Journal of Alzheimer's Disease</i> , 2021, 80, 885-893.	2.6	9
283	Transcranial Doppler Ultrasound in Migraine and Tension-Type Headache After Apomorphine Administration: Double-Blind Crossover Versus Placebo Study. <i>Cephalalgia</i> , 1995, 15, 399-403.	3.9	9
284	Alexithymia may modulate decision making in patients with de novo Parkinson's disease. <i>Functional Neurology</i> , 2011, 26, 127-31.	1.3	9
285	What Does the Brain Have to Keep Working at Its Best? Resilience Mechanisms Such as Antioxidants and Brain/Cognitive Reserve for Counteracting Alzheimer's Disease Degeneration. <i>Biology</i> , 2022, 11, 650.	2.8	9
286	ELECTROPHYSIOLOGICAL EVALUATION OF GENITO-SPHINCTERIC DYSFUNCTION IN MULTIPLE SYSTEM ATROPHY. <i>International Journal of Neuroscience</i> , 2003, 113, 1353-1369.	1.6	8
287	Long-term clinical evaluation in patients with Parkinson's disease and early autonomic involvement. <i>Parkinsonism and Related Disorders</i> , 2006, 12, 279-283.	2.2	8
288	Risk factors for impulse control disorders and related behaviors in Parkinson's disease: secondary analyses of the ICARUS study. <i>Journal of Drug Assessment</i> , 2019, 8, 159-166.	2.2	8

#	ARTICLE	IF	CITATIONS
289	Freezing of gait and dementia in parkinsonism: A retrospective caseâ€“control study. Brain and Behavior, 2019, 9, e01247.	2.2	8
290	Prevalence and Clinical Correlates of Comorbid Anxiety and Panic Disorders in Patients with Parkinsonâ€™s Disease. Journal of Clinical Medicine, 2021, 10, 2302.	2.4	8
291	Locus Coeruleus magnetic resonance imaging in cognitively intact elderly subjects. Brain Imaging and Behavior, 2021, , 1.	2.1	8
292	Altered Neuroendocrine Regulation of Luteinizing Hormone Secretion in Postmenopausal Women with Parkinsonâ€™s Disease. Neuroendocrinology, 1991, 53, 549-555.	2.5	7
293	Relationship Between Neuropsychiatric Symptoms and Cognitive Performance in De Novo Parkinsonâ€™s Disease. Journal of Neuropsychiatry and Clinical Neurosciences, 2012, 24, E22-E23.	1.8	7
294	Levetiracetamâ€“responsive myoclonus in spinocerebellar ataxia type 15. Movement Disorders, 2013, 28, 1465-1465.	3.9	7
295	Mild Depressive Symptoms are Associated With Enhanced Affective Theory of Mind in Nonclinical Adult Women. Journal of Neuropsychiatry and Clinical Neurosciences, 2014, 26, E63-E64.	1.8	7
296	Gynecomastia in epileptics treated with phenobarbital, phenytoin and fluorestone: Two case reports. Italian Journal of Neurological Sciences, 1983, 4, 207-210.	0.1	6
297	The acute convulsant effect of MPTP is dependent on intracerebral MPP+. Neuroscience Letters, 1991, 124, 22-26.	2.1	6
298	Motor expression of kainic acid seizures is attenuated by dopamine depletion in mice. Brain Research, 1994, 657, 269-274.	2.2	6
299	Comparison of teniloxazine and piracetam in alzheimer-type or vascular dementia. Current Therapeutic Research, 1995, 56, 250-257.	1.2	6
300	SUNA Syndrome With Seasonal Pattern. Headache, 2009, 49, 912-914.	3.9	6
301	A case of idiopathic low CSF pressure headache presenting as cough headache. Neurological Sciences, 2010, 31, 789-791.	1.9	6
302	Iowa gambling task in de novo Parkinson's disease: A comparison between good and poor performers. Movement Disorders, 2012, 27, 330-332.	3.9	6
303	From Aberrant Salience to Jumping to Conclusions. Journal of Clinical Psychopharmacology, 2013, 33, 149-151.	1.4	6
304	Novel <i>MTCYB</i> mutation in a young patient with recurrent strokeâ€“like episodes and status epilepticus. American Journal of Medical Genetics, Part A, 2014, 164, 2922-2925.	1.2	6
305	Bipolar Spectrum disorders in Parkinsonâ€™s disease: a systematic evaluation. CNS Spectrums, 2022, 27, 355-361.	1.2	6
306	Subcutaneous Apomorphine for Neuroleptic Malignant Syndrome. American Journal of Psychiatry, 2006, 163, 1450.	7.2	6

#	ARTICLE	IF	CITATIONS
307	Impairment of Affective Theory of Mind in Corticobasal Degeneration. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2012, 24, E7-E7.	1.8	5
308	Functional magnetic resonance imaging with encoding task in patients with mild cognitive impairment and different severity of leukoaraiosis. <i>Psychiatry Research - Neuroimaging</i> , 2018, 282, 126-131.	1.8	5
309	Botulinum toxin for the treatment of dystonia and pain in corticobasal syndrome. <i>Brain and Behavior</i> , 2019, 9, e01182.	2.2	5
310	Is DAT imaging abnormality in normal pressure hydrocephalus always suggestive of degeneration?. <i>Neurological Sciences</i> , 2021, 42, 723-726.	1.9	5
311	Neuroleptic Malignant Syndrome: Further Lessons From a Case Report. <i>Psychosomatics</i> , 2010, 51, 349-354.	2.5	5
312	NREM sleep transient events in fronto-temporal dementia: beyond sleep stage architecture. <i>Archives Italiennes De Biologie</i> , 2015, 153, 214-24.	0.4	5
313	A case of pelvic floor myoclonic jerk syndrome. <i>Movement Disorders</i> , 1996, 11, 331-333.	3.9	4
314	Decision-Making Impairment in a Patient With New Concomitant Diagnoses of Parkinson's Disease and HIV. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2009, 21, 352-353.	1.8	4
315	Out-of-Control Sexual Behavior in an Orbitofrontal Cortex-Damaged Elderly Patient. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2010, 22, 247.e7-247.e7.	1.8	4
316	A pilot psychometric study of aberrant salience state in patients with Parkinson's disease and its association with dopamine replacement therapy. <i>Neurological Sciences</i> , 2014, 35, 1603-1605.	1.9	4
317	Theory of mind in Parkinson's disease: evidences in drug-naïve patients and longitudinal effects of dopaminergic therapy. <i>Neurological Sciences</i> , 2020, 41, 2761-2766.	1.9	4
318	Properties of 3H-MPTP binding sites in human blood platelets. <i>Life Sciences</i> , 1986, 39, 1885-1891.	4.3	3
319	Impaired attention modulation of the blink reflex R3 component in Parkinson's disease: a non-task warning paradigm study. <i>International Journal of Psychophysiology</i> , 2002, 44, 83-91.	1.0	3
320	From Narcissistic Personality Disorder to Frontotemporal Dementia: A Case Report. <i>Behavioural Neurology</i> , 2011, 24, 173-176.	2.1	3
321	Intra-arterial tissue plasminogen activator and abciximab in patients with acute basilar artery occlusion. <i>Neurological Sciences</i> , 2013, 34, 1871-1873.	1.9	3
322	Progressive Impairment of Decision-Making in Behavioral-Variant Frontotemporal Dementia. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2013, 25, E20-E21.	1.8	3
323	Cardioembolic Profile in Patients with Ischemic Stroke: Data from the Analysis of 1037 Cases. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2015, 24, 1287-1290.	1.6	3
324	Imaging in Glucocerebrosidase-Associated Parkinsonism: Current Status and Implications for Pathophysiology. <i>Neurodegenerative Diseases</i> , 2015, 15, 271-280.	1.4	3

#	ARTICLE	IF	CITATIONS
325	Acute encephalopathy of the temporal lobes leading to m.3243A > G. When MELAS is not always MELAS. <i>Mitochondrion</i> , 2016, 30, 148-150.	3.4	3
326	Connected speech in progressive supranuclear palsy: a possible role in differential diagnosis. <i>Neurological Sciences</i> , 2021, 42, 1483-1490.	1.9	3
327	From narcissistic personality disorder to frontotemporal dementia: a case report. <i>Behavioural Neurology</i> , 2011, 24, 173-6.	2.1	3
328	Psychometric properties of the Italian version of the Scales for Outcomes in Parkinson's disease-in Parkinson's disease- Cognition (SCOPA-Cog). <i>Functional Neurology</i> , 0, , .	1.3	3
329	Association study between the DNMT3A -448A>G polymorphism and risk of Alzheimer's disease in Caucasians of Italian origin. <i>American Journal of Neurodegenerative Disease</i> , 2016, 5, 85-93.	0.1	3
330	Motor Response to Apomorphine in Patients With Parkinson's Disease With Long-Duration Response to Levodopa. <i>Clinical Neuropharmacology</i> , 2002, 25, 119-121.	0.7	2
331	Introduction. <i>Parkinsonism and Related Disorders</i> , 2009, 15, S1.	2.2	2
332	Ischemic stroke in patients on oral anticoagulant therapy for a cardioembolic risk factor: always due to cardioembolism?. <i>Neurological Sciences</i> , 2013, 34, 1703-1704.	1.9	2
333	Mediterranean spotted fever: an unusual clinical and neuroradiological presentation. <i>Neurological Sciences</i> , 2015, 36, 2141-2143.	1.9	2
334	RE response to: "Entacapone, Parkinson's disease, "functional adrenergic denervation", and Takotsubo syndrome" <i>Parkinsonism and Related Disorders</i> , 2015, 21, 427.	2.2	2
335	Mild Cognitive Impairment in de novo Parkinson's Disease: Selective Attention Deficit as Early Sign of Neurocognitive Decay. <i>Frontiers in Psychology</i> , 2021, 12, 546476.	2.1	2
336	Platelet monoamine oxidase in dementia of Alzheimer type. <i>Pharmacological Research Communications</i> , 1988, 20, 52.	0.2	1
337	Peripheral-type benzodiazepine receptors in human blood cells of patients affected by migraine without aura. <i>Neurochemistry International</i> , 2000, 37, 363-368.	3.8	1
338	Contribution of cerebellum and brainstem in the control of eye movement: evidence from a functional study in a clinical model. <i>Acta Neurologica Scandinavica</i> , 2002, 105, 32-39.	2.1	1
339	Clozapine for the treatment of levodopa-induced dyskinesias. <i>Lancet Neurology</i> , The, 2004, 3, 268.	10.2	1
340	Variant of Rett Syndrome and CDKL5 Gene: Clinical and Autonomic Description of 10 Cases. <i>Neuropediatrics</i> , 2013, 44, 237-238.	0.6	1
341	Corticobasal Syndrome Presenting With Partial Gerstmann's Syndrome and Digit Agnosia. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2013, 25, E70-E70.	1.8	1
342	A Pilot Study Evaluating the Contribution of SLC19A1(RFC-1) 80G>A Polymorphism to Alzheimer's Disease in Italian Caucasians. <i>BioMed Research International</i> , 2014, 2014, 1-6.	1.9	1

#	ARTICLE	IF	CITATIONS
343	Dopamine Agonist Modifies Cortical Activity in Parkinson Disease. <i>Clinical Neuropharmacology</i> , 2014, 37, 166-172.	0.7	1
344	P058. Refractory chronic migraine, fatigue and OnabotulinumtoxinA: a clinic setting experience. <i>Journal of Headache and Pain</i> , 2015, 16, A113.	6.0	1
345	P041. Analysis of body mass index, psychiatric comorbidity, sleep-wake pattern and occurrence of fatigue in episodic and chronic migraine patients. <i>Journal of Headache and Pain</i> , 2015, 16, A188.	6.0	1
346	Chronic Migraine With Medication Overuse and OnabotulinumtoxinA: Two Positive Case Reports of a Modified Injection Protocol. <i>Headache</i> , 2016, 56, 402-403.	3.9	1
347	Longitudinal changes in MoCA performances in patients with mild cognitive impairment and small vessel disease. Results from the VMCI-Tuscany Study. <i>Cerebral Circulation - Cognition and Behavior</i> , 2021, 2, 100008.	0.9	1
348	Dissecting the Interplay Between Time of Dementia and Cognitive Profiles in Lewy Body Dementias. <i>Journal of Alzheimer's Disease</i> , 2021, 84, 757-766.	2.6	1
349	Phenobarbital prophylaxis of post traumatic epilepsy. <i>Neurological Sciences</i> , 1979, 1, 223-230.	1.9	0
350	Seizures and movement disorders precipitated by drugs. , 2001, , 465-510.		0
351	How many parkinsonian patients are suitable candidates for deep brain stimulation of subthalamic nucleus? Results of a questionnaire. <i>Parkinsonism and Related Disorders</i> , 2008, 14, 266-267.	2.2	0
352	Decision-Making Impairment May Precede Limb Apraxia in Corticobasal Degeneration. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2011, 23, E29-E29.	1.8	0
353	Impulsivity Is Associated With Decision-Making Deficits in De-Novo Parkinson's Disease. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2011, 23, E26-E26.	1.8	0
354	Paroxysmal exertion-induced dystonia secondary to Erdheim-Chester disease. <i>Clinical Neurology and Neurosurgery</i> , 2013, 115, 1105-1106.	1.4	0
355	Reply: Dopamine agonists and delusional jealousy in Parkinson's disease: A cross-sectional prevalence study. <i>Movement Disorders</i> , 2013, 28, 689-690.	3.9	0
356	D5â€¦Oxytocin plasma levels as predictor of social cognition in huntingtonâ€™s disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, A35.2-A35.	1.9	0
357	F5â€¦Social cognition in huntingtonâ€™s disease: evidence from a prospective study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, A50.1-A50.	1.9	0
358	Red blood cell Î±â€¦synuclein heteroaggregates can discriminate healthy controls from cognitively impaired subjects of the ADâ€¦LBD spectrum. <i>Alzheimer's and Dementia</i> , 2020, 16, e040618.	0.8	0
359	Sex differences in red blood cell Î±â€¦synuclein protein and its heteroaggregates with amyloidâ€™ ² and tau in early Alzheimerâ€™s disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e042079.	0.8	0
360	Assessment of the integrity of the noradrenergic nucleus locus coeruleus during normal ageing by neuromelaninâ€™T MRI. <i>Alzheimer's and Dementia</i> , 2020, 16, e043332.	0.8	0

#	ARTICLE	IF	CITATIONS
361	In vivo assessment of the noradrenergic nucleus locus coeruleus in Alzheimer's disease and other types of dementia. <i>Alzheimer's and Dementia</i> , 2020, 16, e043616.	0.8	0
362	Decision-Making Impairment in a Patient With New Concomitant Diagnoses of Parkinson's Disease and HIV. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2009, 21, 352-353.	1.8	0